Other variants, such as those in HSD17B13 and MAMSTR, were found to have larger effects on cirrhosis compared with NAFLD, indicating a more dominant role in the progression to clinically advanced stages of chronic liver disease. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatotic liver disease.